BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7910754)

  • 1. Effects of medication history on midlatency auditory evoked responses in schizophrenia.
    Erwin RJ; Shtasel D; Gur RE
    Schizophr Res; 1994 Feb; 11(3):251-8. PubMed ID: 7910754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midlatency auditory evoked responses in schizophrenia.
    Erwin RJ; Mawhinney-Hee M; Gur RC; Gur RE
    Biol Psychiatry; 1991 Sep; 30(5):430-42. PubMed ID: 1932393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Auditory event-related potentials and electrodermal activity in medicated and unmedicated schizophrenics.
    Roth WT; Goodale J; Pfefferbaum A
    Biol Psychiatry; 1991 Mar; 29(6):585-99. PubMed ID: 1675890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication.
    Stefánsson SB; Jónsdóttir TJ
    Biol Psychiatry; 1996 Jul; 40(1):19-27. PubMed ID: 8780851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The P50 component of the auditory evoked potential and subtypes of schizophrenia.
    Boutros N; Zouridakis G; Rustin T; Peabody C; Warner D
    Psychiatry Res; 1993 Jun; 47(3):243-54. PubMed ID: 8372162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
    Moxon KA; Gerhardt GA; Adler LE
    Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed peak latency of the mismatch negativity in schizophrenics and alcoholics.
    Kathmann N; Wagner M; Rendtorff N; Engel RR
    Biol Psychiatry; 1995 May; 37(10):754-7. PubMed ID: 7640331
    [No Abstract]   [Full Text] [Related]  

  • 8. Event-related potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia.
    Egan MF; Duncan CC; Suddath RL; Kirch DG; Mirsky AF; Wyatt RJ
    Schizophr Res; 1994 Feb; 11(3):259-71. PubMed ID: 7910755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N2 and P3 components of event-related potential in first-episode schizophrenic patients: scalp topography, medication, and latency effects.
    Demiralp T; Uçok A; Devrim M; Isoglu-Alkaç U; Tecer A; Polich J
    Psychiatry Res; 2002 Aug; 111(2-3):167-79. PubMed ID: 12374634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients.
    Freedman R; Adler LE; Waldo MC; Pachtman E; Franks RD
    Biol Psychiatry; 1983 May; 18(5):537-51. PubMed ID: 6134559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The P 300 potential in schizophrenia].
    Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
    Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.
    Hong X; Chan RC; Zhuang X; Jiang T; Wan X; Wang J; Xiao B; Zhou H; Jiang L; Weng B
    Schizophr Res; 2009 Mar; 108(1-3):151-7. PubMed ID: 19106034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of maximum variability within event related potentials in schizophrenia.
    Anderson J; Rennie C; Gordon E; Howson A; Meares R
    Psychiatry Res; 1991 Oct; 39(1):33-44. PubMed ID: 1685249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERPs in schizophrenia: effects of antipsychotic medication.
    Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A
    Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.
    Adler LE; Olincy A; Cawthra EM; McRae KA; Harris JG; Nagamoto HT; Waldo MC; Hall MH; Bowles A; Woodward L; Ross RG; Freedman R
    Am J Psychiatry; 2004 Oct; 161(10):1822-8. PubMed ID: 15465979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latency increase of auditory-evoked potential component N1 predicts poor neuroleptic response in schizophrenic patients.
    Adler G; Markert U; Gattaz WF
    Pharmacopsychiatry; 1994 Mar; 27(2):68-9. PubMed ID: 7913236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain potential evidence for an auditory sensory memory deficit in schizophrenia.
    Catts SV; Shelley AM; Ward PB; Liebert B; McConaghy N; Andrews S; Michie PT
    Am J Psychiatry; 1995 Feb; 152(2):213-9. PubMed ID: 7840354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia, psychoticism, neuroleptics, and auditory evoked potentials.
    Schlör KH; Moises HW; Haas S; Rieger H
    Pharmacopsychiatry; 1985 Sep; 18(5):293-6. PubMed ID: 4048264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Auditory processing in schizophrenia during the middle latency period (10-50 ms): high-density electrical mapping and source analysis reveal subcortical antecedents to early cortical deficits.
    Leavitt VM; Molholm S; Ritter W; Shpaner M; Foxe JJ
    J Psychiatry Neurosci; 2007 Sep; 32(5):339-53. PubMed ID: 17823650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal auditory sensory gating-out in first-episode and never-medicated paranoid schizophrenia patients: an fMRI study.
    Ji B; Mei W; Zhang JX; Jing J; Wu Q; Zhuo Y; Xiao Z
    Exp Brain Res; 2013 Aug; 229(2):139-47. PubMed ID: 23820976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.